- Completed constructive and collaborative in-person Type A meeting with U.S. Food and Drug Administration (FDA) on November 12th for apitegromab biologics license application (BLA) for the treatment of children and adults with spinal muscular atrophy (SMA)
- Catalent Indiana, LLC (part of Novo Nordisk) participated in the Type A meeting in person and presented the progress made in implementing the remediation plan; confirmed to FDA that the site is on-track to be reinspection ready by the end of this year
- Resubmission of BLA and U.S. launch following approval of apitegromab for children and adults with SMA anticipated in 2026
- Timelines accelerated with additional apitegromab U.S. fill-finish facility; tech transfer underway with commercial capacity reserved beginning in Q1 2026
- Dosing underway in Phase 2 OPAL study evaluating apitegromab in infants and toddlers
Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Scholar Rock Holding Corporation on 6ix
In the deck
Earlier from Scholar Rock
- Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference
- Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025
- FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility
- Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment
- Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress
Later from Scholar Rock
- Scholar Rock to Present at Upcoming Investor Conferences
- Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Scholar Rock Highlights 2026 Strategic Priorities
- Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
Follow Scholar Rock into a list and get an email when it puts out news.
Follow Scholar Rock